The purpose of this study is to evaluate the role of patients' response expectations for nocebo side effects, quality of life and adherence during adjuvant endocrine treatment (AET). Furthermore, this study analyses the effects of a structured treatment information on patients' satisfaction with information, response expectations, knowledge and adherence.
The majority of breast cancer patients discontinues today's standard adjuvant treatment (endocrine therapy) due to side effects and reduced quality of life. Thereby, most side effects are unspecific, suggesting a role of psychological factors as patients´ expectations (nocebo effects). Moreover, patients are not informed sufficiently about their treatment. Using a longitudinal design, the nature and onset of adverse side effects and their association to treatment related expectations are investigated. Postoperative patients with hormone receptor-positive breast cancer are assessed before the start of adjuvant treatment. All patients receive standardized, additional information about endocrine therapy. Expectations about side effects, knowledge and satisfaction with the enhanced information are assessed before and after informing patients. Side effects, quality of life and adherence are measured three months, two and five years after start of medication intake. It will be analyzed if patients' response expectations predict side effects and quality of life during medication intake to provide insights into pathways of clinical nocebo effects. Further, this study examines the effects of a structured treatment information on patients' satisfaction with information, response expectations, knowledge and adherence. The study findings promise significant advances in the clinical nocebo research with strong implications for clinical and research practice.
Study Type
OBSERVATIONAL
Enrollment
138
Enhanced information about endocrine therapy, extending clinical routine information
Philipps University Marburg Medical Center
Marburg, Hesse, Germany
Adverse Side Effects
General Assessment of Side Effects (GASE)
Time frame: up to 5 years
Quality of Life
European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) with breast module (QLQ-BR23)
Time frame: up to 5 years
Adherence
Medication Adherence Report Scale (MARS-D); Adherence with endocrine treatment; reasons for non-adherence
Time frame: up to 5 years
Knowledge
Patients' knowledge of hormone receptor status of their tumor
Time frame: up to 5 years
Satisfaction with Information
Satisfaction with Information about Medicines Scale, (SIMS-D)
Time frame: Baseline
Expectations
General Assessment of Side Effects Scale - Expectations Module
Time frame: Baseline
Coping with Side Effects
General Assessment of Side Effects Scale -Coping Module
Time frame: Follow-up (3 months, 2 years, 5 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.